Rapamycin-Related Problems Probed
Treatment with rapamycin may be associated with myoglobinuria and severe acute renal failure (ARF) following renal transplantation, according to a new study.
Treatment with rapamycin may be associated with myoglobinuria and severe acute renal failure (ARF) following renal transplantation, according to a new study.
TORONTO—A new online communication system under development promises to allow the tracking of every tissue or organ from donor to recipient in the United States. Such a system could reduce morbidity and mortality from donor-derived diseases.
Naftopidil is effective first-line monotherapy for patients with storage symptoms associated with benign prostatic hyperplasia (BPH), according to researchers in Japan.
PHILADELPHIA—Prostate cancer patients treated with luteinizing hormone- releasing hormone (LHRH) have increased bone turnover and rapid bone loss within six months. A recent study suggests that this can be prevented with risedronate 35 mg once a week.
While coverage of wrong-side, wrong-site, wrong-procedure, and wrong-patient surgery occasionally appears in the lay press, it has been virtually nonexistent in the medical literature.
A jury in Staten Island, N.Y., awarded $3.9 million to a man who experienced complications following vascular surgery.
Medical errors caused by missed and delayed diagnoses in the outpatient setting result in significant harm to patients, according to a recent review of medical malpractice claims.
African-American (AA) men with nonpalpable prostate cancer have greater cancer volumes and higher prostatectomy Gleason scores than white men with similar PSA levels at the time of biopsy, according to a study.
Dr. R is a successful urologist who had gathered a wide circle of referring physicians over his 15 years in urologic practice, and he prided himself on his diagnostic acumen. But a missed case of prostate cancer dragged him into a malpractice suit.
PSA levels and PSA doubling time (PSADT) prior to radiotherapy predict outcomes following rescue radiation therapy for men with prostate cancer.